Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 4, 1996, Pages 846-851

  Thackray, Alana M ^a   Field, Hugh J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HERPES SIMPLEX VIRUS 2; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; SKIN INFECTION; VIRUS INHIBITION; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 0029966588     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.4.846     Document Type: Article

References (24)

1. Bacon, T. H., and R. F. Schinazi. 1993. An overview of the further evaluation of penciclovir against herpes simplex virus and varicella-zoster virus in cell culture highlighting contrasts with acyclovir. Antiviral Chem. Chemother. 4(Suppl. 1):25-36.
2. Beauchamp, L. M., G. F. Orr, P. de Miranda, T. Burnette, H. J. Schaeffer, and T. A. Krenitsky. 1992 Amino acid ester prodrugs of acyclovir. Antiviral Chem. Chemother. 3:157-164.
3. Blyth, W. A., D. A. Harbour, and T. J. Hill. 1980. Effect of acyclovir on recurrence of herpes simplex skin lesions in mice. J. Gen Virol. 48:417-419.
4. Boyd, M. R., S. Safrin, and E. R. Kern. 1993. Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem. Chemother. 4(Suppl 1):3-11.
5. Earnshaw, D. C., T. H. Bacon, S. J. Darlison, K. Edmonds, R, M. Perkins, and R. A. Vere Hodge. 1992. Penciclovir: mode of action of penciclovir in MRC-5 cells infected with herpes simplex virus (HSV-1), HSV-2 and varicella-zoster virus. Antimicrob. Agents Chemother. 36:2747-2757.
6. Field, H. J., S. E. Bell, G. B. Elion, A. A. Nash, and P. Wildy. 1979. Effect of acycloguanosine treatment on acute and latent herpes simplex infections in mice. Antimicrob. Agents Chemother. 15:554-561.
7. Field, H. J., and E. DeClercq. 1981. Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. J. Gen. Virol. 56:259-265.
8. Field, H. J., D. Tewari, D. Sutton, and A. M. Thackray. 1995. Comparison of eificacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. Antimicrob. Agents Chemother. 39: 1114-1119.
9. Field, H. J., and A. M. Thackray. 1995. The effects of delayed-onset chemotherapy using famciclovir or valaciclovir in a murine immunosuppression model for HSV-1. Antiviral Chem. Chemother. 6:210-216.
10. Field, H. J., and A. M. Thackray. 1995 Famciclovir and valaciclovir treatment during acute HSV-1 infection of mice have markedly different effects on subsequent virus reactivation from ganglia. Antiviral Res. 26:A232.
11. Field, H. J., and P. Wildy. 1978 The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J. Hyg. Camb. 81:267-277.
12. Harnden, M. R., R. L. Jarvest, M. R. Boyd, D. Sutton, and R. A. Vere Hodge. 1989. Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved absorption properties. J. Med. Chem. 32:1738-1743.
13. Klein, R. J., and A. E. Friedman-Kien. 1985. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency Antimicrob. Agents Chemother. 27:763-768.
14. Klein, R. J., A. E. Friedman-Kien, and E. DeStefano. 1979. Latent herpes simplex infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother. 15:723-729.
15. Klein, R. J., A. E. Friedman-Kien, and E. DeStefano. 1983. Effect of discontinuous acyelovir treatment on in vitro reactivation of herpes simplex virus from latently infected trigeminal ganglia. Antimicrob. Agents Chemother. 24:129-131
16. Klein, R. J., A. E. Friedman-Kien, L. Kaley, and E. Brady. 1984 Effects of topical applications of phosphonoacetate on colonization of mouse trigeminal ganglia with herpes simplex virus type 1. Antimicrob Agents Chemother. 26:65-68.
17. Nash, A. A., H. J. Field, and R. Quartey-Papafio. 1980. Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterisation and antiviral effects of delayed type hypersensitivity. J. Gen. Virol. 48:351-357.
18. Sutton, D., and M. R. Boyd. 1993 Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob. Agents Chemother 37:642-645.
19. Thackray, A. M., and H. J. Field. 1996. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect Dis. 173:291-299.
20. Thouless, M. E. 1972 Scrological properties of thymidine kinase produced in cells infected with type 1 or type 2 herpes virus. J Gen. Virol. 17:307-315.
21. Vere Hodge, R. A. 1993. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother. 4:67-84.
22. Vere Hodge, R. A., and R. M. Perkins. 1989. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-y1)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. 33:223-229
23. Vere Hodge, R. A., D. Sutton, M. R. Boyd, M. R. Harnden, and R. L. Jarvest. 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent (BRL 39123) [9-(4-hydroxy-3-hydroxymethylbut-1-y1) guanine; penciclovir]. Antimicrob Agents Chemother. 33:1765-1773
24. Weller, S., M. R. Blum, M. Doucette, T. Burnette, D. M. Cederberg, P. de Miranda, and L. M. Smiley. 1993. Pharmacokinetics of the acyclovir prodrug valaciclovir after escalating single and multiple-dose administration to normal volunteers. Clin. Pharm. Ther. 54:595-605.